Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1

JS Wijpkema; PL van Haelst; PS Monraats; M Bruinenberg; AH Zwinderman; F Zijlstra; G van der Steege; RJ de Winter; PAFM Doevendans; J Waltenberger; JW Jukema; RA Tio

Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1

JS Wijpkema, PL van Haelst, PS Monraats, M Bruinenberg, AH Zwinderman, F Zijlstra, G van der Steege, RJ de Winter, PAFM Doevendans, J Waltenberger, JW Jukema, RA Tio^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

30 Citations (Scopus)

Abstract

Objectives The renin-angiotensin system (RAS) is thought to play a major role in the pathophysiology of de-novo restenotic lesions and in-stent restenosis after percutaneous coronary intervention (PCI). Heme oxygenase-1 (HO-1), is thought to beneficially influence these processes. We examined the effect of pharmacologic as well as genetic RAS interactions on restenosis in a large population of consecutive patients undergoing PCI, and evaluated possible gene-gene interactions in both systems.

Methods The GENDER project is a multicenter prospective follow-up study, including 3146 patients after successful PCI. Genotyping in these patients was performed for the ACE gene insertion/deletion, the angiotensinogen 235Met/Thr, T174M and A(-6)G, the angiotensin-II type 1 receptor (AT1R) 1166A/C and T81OA, the angiotensin-II type 2 receptor (AT2R) 1675G/A and 3123A polymorphisms and the length polymorphism in the HO-1 promoter region.

Results A total of 3104 patients were followed for 10 months. In 2975 patients at least one of the nine genotypes could be determined. The AT1R 1166 CC genotype showed a significant association with TVR; the other polymorphisms did not. RAS-inhibitory drugs were not associated with the incidence of TVR, nor did they interact with any of the investigated polymorphisms. Patients with the ACE I/I polymorphism showed a trend towards a better outcome if they had a short number of repeats in the HO-1 promoter. This relationship was inversely present in carriers of the ACE D/D polymorphism.

Conclusion We could only establish a role for the AT1R 1166A/C polymorphism in restenosis after PCI. However, significant gene-gene interaction was suggested for the ACE gene and the HO-1 promotor. The RAS and HO-1 relation in restenosis merits further investigation. Pharmacogenetics and Genomics 16:331-337 (c) 2006 Lippincott Williams & Wilkins.

Original language	English
Pages (from-to)	331-337
Number of pages	7
Journal	PHARMACOGENETICS AND GENOMICS
Volume	16
Issue number	5
Publication status	Published - May-2006

Keywords

angiotensins
renin-angiotensin system
hemeoxygenase 1
single nucleotide polymorphism
coronary restenosis
angioplasty
PLACEBO-CONTROLLED TRIAL
MICROSATELLITE POLYMORPHISM
ARTERY DISEASE
BLOOD-PRESSURE
GENE PROMOTER
BALLOON ANGIOPLASTY
RISK-FACTORS
DOUBLE-BLIND
IN-VIVO
SYSTEM

Handle.net

Persistent link

Fingerprint

Dive into the research topics of 'Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1'. Together they form a unique fingerprint.

Cite this

Wijpkema, JS., van Haelst, PL., Monraats, PS., Bruinenberg, M., Zwinderman, AH., Zijlstra, F., van der Steege, G., de Winter, RJ., Doevendans, PAFM., Waltenberger, J., Jukema, JW., & Tio, RA. (2006). Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1. PHARMACOGENETICS AND GENOMICS, 16(5), 331-337.

Wijpkema, JS ; van Haelst, PL ; Monraats, PS et al. / Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1. In: PHARMACOGENETICS AND GENOMICS. 2006 ; Vol. 16, No. 5. pp. 331-337.

@article{4183e1630d2e4c3ebce2dabb8aab98ab,

title = "Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1",

abstract = "Objectives The renin-angiotensin system (RAS) is thought to play a major role in the pathophysiology of de-novo restenotic lesions and in-stent restenosis after percutaneous coronary intervention (PCI). Heme oxygenase-1 (HO-1), is thought to beneficially influence these processes. We examined the effect of pharmacologic as well as genetic RAS interactions on restenosis in a large population of consecutive patients undergoing PCI, and evaluated possible gene-gene interactions in both systems.Methods The GENDER project is a multicenter prospective follow-up study, including 3146 patients after successful PCI. Genotyping in these patients was performed for the ACE gene insertion/deletion, the angiotensinogen 235Met/Thr, T174M and A(-6)G, the angiotensin-II type 1 receptor (AT1R) 1166A/C and T81OA, the angiotensin-II type 2 receptor (AT2R) 1675G/A and 3123A polymorphisms and the length polymorphism in the HO-1 promoter region.Results A total of 3104 patients were followed for 10 months. In 2975 patients at least one of the nine genotypes could be determined. The AT1R 1166 CC genotype showed a significant association with TVR; the other polymorphisms did not. RAS-inhibitory drugs were not associated with the incidence of TVR, nor did they interact with any of the investigated polymorphisms. Patients with the ACE I/I polymorphism showed a trend towards a better outcome if they had a short number of repeats in the HO-1 promoter. This relationship was inversely present in carriers of the ACE D/D polymorphism.Conclusion We could only establish a role for the AT1R 1166A/C polymorphism in restenosis after PCI. However, significant gene-gene interaction was suggested for the ACE gene and the HO-1 promotor. The RAS and HO-1 relation in restenosis merits further investigation. Pharmacogenetics and Genomics 16:331-337 (c) 2006 Lippincott Williams & Wilkins.",

keywords = "angiotensins, renin-angiotensin system, hemeoxygenase 1, single nucleotide polymorphism, coronary restenosis, angioplasty, PLACEBO-CONTROLLED TRIAL, MICROSATELLITE POLYMORPHISM, ARTERY DISEASE, BLOOD-PRESSURE, GENE PROMOTER, BALLOON ANGIOPLASTY, RISK-FACTORS, DOUBLE-BLIND, IN-VIVO, SYSTEM",

author = "JS Wijpkema and {van Haelst}, PL and PS Monraats and M Bruinenberg and AH Zwinderman and F Zijlstra and {van der Steege}, G and {de Winter}, RJ and PAFM Doevendans and J Waltenberger and JW Jukema and RA Tio",

note = "0 Article J",

year = "2006",

month = may,

language = "English",

volume = "16",

pages = "331--337",

journal = "PHARMACOGENETICS AND GENOMICS",

issn = "1744-6872",

publisher = "LIPPINCOTT WILLIAMS & WILKINS",

number = "5",

}

Wijpkema, JS, van Haelst, PL, Monraats, PS, Bruinenberg, M, Zwinderman, AH, Zijlstra, F, van der Steege, G, de Winter, RJ, Doevendans, PAFM, Waltenberger, J, Jukema, JW & Tio, RA 2006, 'Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1', PHARMACOGENETICS AND GENOMICS, vol. 16, no. 5, pp. 331-337.

Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1. / Wijpkema, JS; van Haelst, PL; Monraats, PS et al.
In: PHARMACOGENETICS AND GENOMICS, Vol. 16, No. 5, 05.2006, p. 331-337.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1

AU - Wijpkema, JS

AU - van Haelst, PL

AU - Monraats, PS

AU - Bruinenberg, M

AU - Zwinderman, AH

AU - Zijlstra, F

AU - van der Steege, G

AU - de Winter, RJ

AU - Doevendans, PAFM

AU - Waltenberger, J

AU - Jukema, JW

AU - Tio, RA

N1 - 0 Article J

PY - 2006/5

Y1 - 2006/5

N2 - Objectives The renin-angiotensin system (RAS) is thought to play a major role in the pathophysiology of de-novo restenotic lesions and in-stent restenosis after percutaneous coronary intervention (PCI). Heme oxygenase-1 (HO-1), is thought to beneficially influence these processes. We examined the effect of pharmacologic as well as genetic RAS interactions on restenosis in a large population of consecutive patients undergoing PCI, and evaluated possible gene-gene interactions in both systems.Methods The GENDER project is a multicenter prospective follow-up study, including 3146 patients after successful PCI. Genotyping in these patients was performed for the ACE gene insertion/deletion, the angiotensinogen 235Met/Thr, T174M and A(-6)G, the angiotensin-II type 1 receptor (AT1R) 1166A/C and T81OA, the angiotensin-II type 2 receptor (AT2R) 1675G/A and 3123A polymorphisms and the length polymorphism in the HO-1 promoter region.Results A total of 3104 patients were followed for 10 months. In 2975 patients at least one of the nine genotypes could be determined. The AT1R 1166 CC genotype showed a significant association with TVR; the other polymorphisms did not. RAS-inhibitory drugs were not associated with the incidence of TVR, nor did they interact with any of the investigated polymorphisms. Patients with the ACE I/I polymorphism showed a trend towards a better outcome if they had a short number of repeats in the HO-1 promoter. This relationship was inversely present in carriers of the ACE D/D polymorphism.Conclusion We could only establish a role for the AT1R 1166A/C polymorphism in restenosis after PCI. However, significant gene-gene interaction was suggested for the ACE gene and the HO-1 promotor. The RAS and HO-1 relation in restenosis merits further investigation. Pharmacogenetics and Genomics 16:331-337 (c) 2006 Lippincott Williams & Wilkins.

AB - Objectives The renin-angiotensin system (RAS) is thought to play a major role in the pathophysiology of de-novo restenotic lesions and in-stent restenosis after percutaneous coronary intervention (PCI). Heme oxygenase-1 (HO-1), is thought to beneficially influence these processes. We examined the effect of pharmacologic as well as genetic RAS interactions on restenosis in a large population of consecutive patients undergoing PCI, and evaluated possible gene-gene interactions in both systems.Methods The GENDER project is a multicenter prospective follow-up study, including 3146 patients after successful PCI. Genotyping in these patients was performed for the ACE gene insertion/deletion, the angiotensinogen 235Met/Thr, T174M and A(-6)G, the angiotensin-II type 1 receptor (AT1R) 1166A/C and T81OA, the angiotensin-II type 2 receptor (AT2R) 1675G/A and 3123A polymorphisms and the length polymorphism in the HO-1 promoter region.Results A total of 3104 patients were followed for 10 months. In 2975 patients at least one of the nine genotypes could be determined. The AT1R 1166 CC genotype showed a significant association with TVR; the other polymorphisms did not. RAS-inhibitory drugs were not associated with the incidence of TVR, nor did they interact with any of the investigated polymorphisms. Patients with the ACE I/I polymorphism showed a trend towards a better outcome if they had a short number of repeats in the HO-1 promoter. This relationship was inversely present in carriers of the ACE D/D polymorphism.Conclusion We could only establish a role for the AT1R 1166A/C polymorphism in restenosis after PCI. However, significant gene-gene interaction was suggested for the ACE gene and the HO-1 promotor. The RAS and HO-1 relation in restenosis merits further investigation. Pharmacogenetics and Genomics 16:331-337 (c) 2006 Lippincott Williams & Wilkins.

KW - angiotensins

KW - renin-angiotensin system

KW - hemeoxygenase 1

KW - single nucleotide polymorphism

KW - coronary restenosis

KW - angioplasty

KW - PLACEBO-CONTROLLED TRIAL

KW - MICROSATELLITE POLYMORPHISM

KW - ARTERY DISEASE

KW - BLOOD-PRESSURE

KW - GENE PROMOTER

KW - BALLOON ANGIOPLASTY

KW - RISK-FACTORS

KW - DOUBLE-BLIND

KW - IN-VIVO

KW - SYSTEM

M3 - Article

SN - 1744-6872

VL - 16

SP - 331

EP - 337

JO - PHARMACOGENETICS AND GENOMICS

JF - PHARMACOGENETICS AND GENOMICS

IS - 5

ER -

Wijpkema JS, van Haelst PL, Monraats PS, Bruinenberg M, Zwinderman AH, Zijlstra F et al. Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1. PHARMACOGENETICS AND GENOMICS. 2006 May;16(5):331-337.